the Technology

the Technology

Our Diagnostics Technology

LMScan is a novel, functional biomarker discovery platform for rapid analysis of pro-resolving mechanisms in inflammatory diseases

LMScan determines the identity and concentrations of bioactive lipid mediators in biological samples. This enables the characterization of novel ‘signatures’, with powerful diagnostic and prognostic value, as well as those associated with response to therapy. It underpins the company’s growing portfolio of lipid mediator ‘signatures’ (LMS) or ‘fingerprints’ as Companion Diagnostics (CDx).

Our LMScan platform represents a first-in-class technology which will accelerate the adoption of precision medicines for patient use in inflammatory conditions. The technology applies sophisticated mass-spectrometry-based identification and quantification methodologies which are protected by patent filings and proprietary knowledge. The analysis provides a snapshot of processes occurring in the target tissue and thus can respond to real world needs, such as use in adaptive clinical trial design.

Our initial focus is on, rheumatic disease, cardiovascular disease, sepsis and trauma where substantial unmet need exists.

LMScan will deliver positive outcomes for drug companies, healthcare providers and payors alike.

Our Therapeutics Technology 

ResoCell, is a proprietary cell-based therapeutic platform which enables reprogramming of patient cells to limit inflammatory diseases.

ResoCell has the ability to target cells that are central to disease onset and progression and reprogram them to terminate inflammation and potentially promote the repair of damaged tissues.

 

In contrast to many cell-based therapeutics the ResoCell technology is based on cellular reprogramming methodologies and will take advantage of proprietary, scalable protocols. This technology will be offered with predictive LMS companion diagnostics that can determine the effectiveness of the reprograming step prior to re-injection of cells into the patient, thereby increasing the likelihood that the treatment will be effective.

This technology will initially target rheumatoid arthritis and cardiovascular diseases.

Competitive Advantages

LMScan specifically identifies and quantifies lipid mediators, not lipids

Predicting how a patient’s inflammatory machinery will respond to a given drug requires a technology capable of directly measuring lipid mediator regulation.  In addition, the lipid mediators themselves play important roles in the regulation of endogenous processes, and in some cases the mechanism of action of a given drug might involve up-regulation of these molecules, e.g. statins and aspirin.  Measurement of these molecules can provide a strong and novel indication of drug efficacy.

Competing technologies include those that enable mutational analysis of DNA, mRNA, mRNA transcript measurements (gene expression analysis), or protein abundance measurements (ELISA, IHC).  These methodologies, however, fail to measure the activity and/or expression of target molecules and instead provide surrogates of drug target activation.

 Lipid mediators are structurally and functionally distinct from molecules targeted by general metabolomics platforms. They exert defined and direct biological actions, via the activation of specific receptors. Notably, most metabolites measured by canonical metabolomics platforms do not exert receptor-mediated biological actions.

Distinct lipid mediators display biological activity relevant to how our body operates in health and responds in disease. These attributes differentiate Resolomics’ technologies from existing lipidomic and metabolomic technologies and services providers.  Therefore, results generated using the LMScan platform reflect ongoing dynamic processes in the specific tissue of interest that are functionally relevant to the disease under interrogation.

Publications

Browse through our extensive list of publications

About Resolomics

Enhanced diagnostic signatures for patient stratification and improved clinical management of human diseases

Get in touch
+44 (0)20 7882 5278

info@resolomics.com

Resolomics ltd

William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, Charterhouse Square
LONDON EC1M 6BQ